AstraZeneca has gained approval from the European Commission for its oral therap...
Lilly’s Zepbound has become the first prescription medicine approved to treat ad...
SK bioscience and Sanofi have expanded their agreement to jointly develop pneumo...
Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjuncti...
Palleon and Henlius Biotech have entered into a licence agreement and partnershi...
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic aden...
In this issue: Recent US reproductive laws could limit women’s participation in ...
Vertex said the Phase II trial met its primary endpoint, however there was only ...
Mesoblast has gained US FDA approval for its mesenchymal stromal cell (MSC) ther...
MSD has entered an exclusive global licence agreement with Hansoh Pharma for a p...
The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for r...
Novo Nordisk has announced positive results from its Phase III trial of CagriSem...
The US Food and Drug Administration (FDA) has stood by an earlier decision confi...
The UK's DHSC has announced its anticipated 2025 headline payback rate for new m...
Picking the right clinical partners will be critical for oncology innovators hop...
Improper advertising on media constituted a large part of traffic directed to th...
